LALPATHLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.7
| Stock Code | LALPATHLAB | Market Cap | 22,489 Cr. | Current Price | 1,344 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 41.9 | Book Value | 140 ₹ | Dividend Yield | 0.89 % | ROCE | 30.6 % |
| ROE | 24.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,406 ₹ | DMA 200 | 1,463 ₹ |
| Chg in FII Hold | -1.57 % | Chg in DII Hold | 0.98 % | PAT Qtr | 113 Cr. | PAT Prev Qtr | 146 Cr. |
| RSI | 41.5 | MACD | -18.5 | Volume | 1,76,551 | Avg Vol 1Wk | 2,47,794 |
| Low price | 1,176 ₹ | High price | 1,771 ₹ | PEG Ratio | 3.21 | Debt to equity | 0.06 |
| 52w Index | 28.2 % | Qtr Profit Var | 7.24 % | EPS | 30.8 ₹ | Industry PE | 32.6 |
📊 Chart & Trend Analysis: LALPATHLAB is trading at ₹1,344, below both its 50 DMA (₹1,406) and 200 DMA (₹1,463), indicating bearish momentum. RSI at 41.5 suggests the stock is approaching oversold territory. MACD at -18.5 confirms negative momentum. Bollinger Bands show price leaning towards the lower band, with support near ₹1,176.
📈 Momentum Signals: Current volume (1.76 lakh) is lower than the 1-week average (2.47 lakh), showing reduced participation. Weak RSI and negative MACD reinforce bearish bias, suggesting selling pressure dominates.
💡 Entry Zone: Optimal entry around ₹1,300–1,340 (near support).
🚪 Exit Zone: Resistance seen at ₹1,406 (50 DMA) and ₹1,463 (200 DMA). Profit booking advised near these levels.
🔎 Trend Status: The stock is currently consolidating with bearish bias. A breakout above ₹1,406 would indicate recovery momentum.
Positive
- Strong ROCE (30.6%) and ROE (24.7%) reflect efficient capital use.
- Low debt-to-equity ratio (0.06) ensures financial stability.
- Dividend yield of 0.89% adds investor appeal.
- EPS of ₹30.8 supports earnings visibility.
Limitation
- High P/E (41.9) compared to industry average (32.6) suggests overvaluation.
- Trading below both 50 DMA and 200 DMA highlights weak technical strength.
- PEG ratio of 3.21 indicates expensive valuation relative to growth.
- Volume participation is lower than average, showing reduced market interest.
Company Negative News
- Decline in FII holding (-1.57%) shows reduced foreign investor confidence.
- Sequential PAT decline (₹113 Cr vs ₹146 Cr) indicates margin pressure.
Company Positive News
- DII holding increased (+0.98%), reflecting domestic institutional support.
- Quarterly profit variation (+7.24% YoY) highlights resilience despite sequential decline.
Industry
- Industry P/E at 32.6 is lower than LALPATHLAB’s P/E, suggesting peers may be more attractively valued.
- Diagnostics and healthcare services sector remains resilient, supported by rising demand for preventive health checkups and specialized testing.
Conclusion
⚖️ LALPATHLAB shows strong fundamentals (healthy ROE/ROCE, low debt, dividend yield) but faces valuation concerns and weak technical momentum. Short-term consolidation with bearish bias is evident. Entry near ₹1,300–1,340 offers margin of safety, while exits should be considered near ₹1,406–1,463. Long-term investors may hold for sector resilience, while traders should wait for confirmation above 50 DMA before aggressive buying.
Would you like me to extend this into a peer benchmarking overlay (e.g., comparing LALPATHLAB with Metropolis Healthcare, Dr. Lal’s competitors, and Thyrocare) to highlight relative strength and sector rotation opportunities?